How Data Analytics can Boost the Bottom Line at a CDMO

By innovating their service offerings, CDMOs can address some of the major challenges their partners face when deciding to outsource their operations, like loss of control or quality management. In this webinar, we will propose a scenario in which a CDMO can double the return on investment in just one year! 

OSIsoft and Sartorius Partner to Help CDMOs Leverage their Data

Learn how contract pharma organizations can gain additional insights from their data to become more profitable and increase partner trust. Hear a success story from FUJIFILM Diosynth Biotechnologies, which paired the OSIsoft PI System with advanced data analytics tools to achieve a tenfold optimization in resource expenditure.

How CDMOs can Adopt a Modular PAT Strategy

When CDMOs investigate the use of PAT they must be assured their ROI, therefore the PAT technology they invest in should be versatile and modular – working with a range of processes and modalities. The Sartorius BioPAT® Spectro Raman tool gives CDMOs working in a high-paced environment the opportunity to unlock the full potential of Raman spectroscopy.

Putting the “D” in CDMO with Data Analytics and Ambr®

Biopharmaceutical companies have placed an increased reliance on contract development and manufacturing organizations (CDMOs) for all aspects of process development. However, as a CDMO, how can ensure that you’ll be able to meet the aggressive timeline expectations set out by your clients? In this webinar, Sartorius experts will discuss how to accelerate process development timelines. 

How CDMOs Can Digitalize their Cell and Gene Therapy Processes

One of the most important considerations for companies working in the CGT (cell and gene therapy) field is how to ensure commercial success of the product. By developing a strong relationship with the right CDMO, CGT developers can chart out a development, scale-up, and manufacturing plan that aligns with both their clinical and financial needs.

Application of DOE (Design of Experiments) to Antibody Drug Conjugates (ADC) Process Development

Find out the Piramal approach to the development of Antibody Drug Conjugates processes. Specifically, it will focus on the use of DOE to develop the key reactive stage of a standard ADC process. The impact of process parameters on product quality attribute, namely Drug-to-Antibody ratio was assessed via full factorial design. The analysis of the design was assessed via Sartorius MODDE® 13 software. The software enabled to modelise the effects of parameters, allowing identification of set points for safe upscaling of the process.